Avalo Therapeutics (AVTX) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Avalo Therapeutics (AVTX) overview

Avalo Therapeutics (AVTX) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 0.1m and operating profit of USD -72.9m; the year-end share price was 18.16 USD and market capitalisation was USD 336m. Avalo Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Avalo Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 83.0mFY 2025
Share price18.16 USDFY 2025 year end
RevenueUSD 0.1mFY 2025
Operating profitUSD -72.9mFY 2025
Net earningsUSD -78.3mFY 2025
Market capitalisationUSD 336mFY 2025 year end

About Avalo Therapeutics

Avalo Therapeutics is a clinical-stage biotechnology company developing treatments for immune-mediated inflammatory diseases. Its lead candidate, abdakibart, is an anti-IL-1β monoclonal antibody being studied in a Phase 2 trial for hidradenitis suppurativa. The company also describes plans to develop or acquire additional compounds and programs for these diseases; the supplied text identifies legacy programs that are not currently in clinical development.

Generate the Avalo Therapeutics report

Avalo Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Avalo Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Avalo Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.